Lake Street analyst Ben Haynor lowered the firm’s price target on Sensus Healthcare (SRTS) to $13 from $18 and keeps a Buy rating on the shares after having attended the American Academy of Dermatology annual meeting and noting that Sensus’ largest customer, SkinCure Oncology, submitted for 510(k) clearance of GentleBeam, a competitive SRT unit. Sensus management “seemed unphased by the development,” though the firm is reducing its EPS estimates to account for the development, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS:
- Sensus Healthcare participates in a conference call with Lake Street
- Sensus resumed purchasing of stock under $3M share repurchase program
- Sensus Healthcare’s Strong Revenue Growth and Strategic Initiatives Justify Buy Rating
- Sensus Healthcare price target raised to $12 from $11 at H.C. Wainwright
- Sensus Healthcare Earnings Call Highlights Robust Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue